Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (26): 4927-4930.doi: 10.3969/j.issn.1673-8225.2011.26.044

Previous Articles     Next Articles

Calcitonin promotes implant osteointegration in osteoporosis condition

Chen Bai-ling1, Xie Deng-hui1, Lü Wei-jia2, Li Fo-bao1, Liao Wei-ming1, Li Yi-qiang1   

  1. 1Department of Orthopaedics, First Affiliated Hospital of Sun Yat-sen University, Guangzhou  510080, Guangdong Province, China
    2Department of Traumatology and Orthopedics, Medical College, University of Hong Kong, Hong Kong, China
  • Received:2011-03-05 Revised:2011-05-10 Online:2011-06-25 Published:2011-06-25
  • Contact: Chen Bai-ling, Ph. D., Associate chief physician, Department of Orthopaedics, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China berlinch2007@yahoo.com.cn
  • About author:Chen Bai-ling☆, Ph. D., Associate chief physician, Department of Orthopaedics, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China berlinch2007@yahoo.com.cn Xie Deng-hui, Department of Orthopaedics, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China Chen Bai-ling and Xie Deng-hui contributed equally to this article.

PDF

423

Abstract:

BACKGROUND: Calcitonin can increase bone quantity and quality so as to reduce bone fracture occurrence.
OBJECTIVE: To evaluate the effects of calcitonin on implant’s osteointegration and further on promoting the biological fixation of implants in osteoporotic condition.
METHODS: Sprague-Dawley rats were randomly divided into three groups: sham surgery + hydroxyapatite (HA), ovariectomy (OVX) + HA, and OVX + calcitonin + HA groups. Postmenopausal osteoporosis models were established in the OVX + HA and OVX + calcitonin + HA groups. The porous HA prostheses were inserted into the tibial platform in each group after model induction, and rats in the OVX + calcitonin + HA group were given calcitonin for 12 weeks by subcutaneous injection.
RESULTS AND CONCLUSION: Lumbar vertebral bone mineral density (BMD) decreased in OVX + HA group, and the lumbar BMD increased in the OVX + calcitonin + HA group after administration of calcitonin. Comparing with that in OVX + HA group, osseointegration rate in OVX + calcitonin + HA group was increased by 22.0% (P < 0.05). Results verified that in osteoporotic condition, subcutaneous administration of calcitonin could increase bone mass surrounding the implants and promote osteointegration.

CLC Number: